TheraRadar
Data updated: Jun 28, 2026

SODIUM PHOSPHATES (sodium phosphate, dibasic, heptahydrate) · CAPLIN

Other Approved 2022-03-30

: Sodium Phosphates Injection, USP, 3 mM P/mL is indicated as a source of phosphorus, for addition to large volume intravenous fluids, to prevent or correct hypophosphatemia in patients with restricted or no oral intake. It is also useful as an additive for preparing specific parenteral fluid formulas when the needs of the patient cannot be met by standard electrolyte or nutrient solutions.

Source: FDA Label
3
Indications
--
Phase 3 Trials
4
Years on Market

Details

Status
Prescription
First Approved
2022-03-30
Routes
INTRAVENOUS
Dosage Forms
SOLUTION

SODIUM PHOSPHATES Approval History

2023
2024
2025
2026
Original
New Indication
New Form
Label Update
9 FDA actions from 2022 to 2026
Feb 2026 ORIGINAL
Update
Jun 2024 ORIGINAL
Update
Mar 2022 ORIGINAL
Update

What SODIUM PHOSPHATES Treats

1 indications

SODIUM PHOSPHATES is approved for 1 conditions since its original approval in 2022. These indications span multiple therapeutic areas including oncology, immunology, and more.

  • Hypophosphatemia
Source: FDA Label

SODIUM PHOSPHATES Competitive Set

Pro

Three rings of competition based on shared molecular targets and treated indications.

Indication competitors

2

Same indication, different mechanism — what else might this patient receive?

Filters applied: drops same-active-ingredient (505(b)(2) reformulations), route-mismatch (topical vs systemic), and cross-therapeutic-area matches in same-indication rings.

Drugs Similar to SODIUM PHOSPHATES

FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.

POTASSIUM PHOSPHATES
POTASSIUM PHOSPHATE, DIBASIC
1 shared
Fresenius Kabi
Shared indications:
Hypophosphatemia
POTASSIUM PHOSPHATES IN 0.9% SODIUM CHLORIDE
POTASSIUM PHOSPHATE, DIBASIC
1 shared
Fresenius Kabi
Shared indications:
Hypophosphatemia
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

Full development history with FDA approval milestones

|
Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

SODIUM PHOSPHATES FDA Label Details

Indications & Usage

: Sodium Phosphates Injection, USP, 3 mM P/mL is indicated as a source of phosphorus, for addition to large volume intravenous fluids, to prevent or correct hypophosphatemia in patients with restricted or no oral intake. It is also useful as an additive for preparing specific parenteral fluid formulas when the needs of the patient cannot be met by standard electrolyte or nutrient solutions. The concomitant amount of sodium (Na + 4 mEq/mL) must be calculated into total electrolyte dose of such prepared solutions.

Track SODIUM PHOSPHATES with TheraRadar Pro

Watchlist alerts, full database access, CSV exports across 14,000+ drugs.

Upgrade to Pro

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.